NeoGenomics (NEO) News Today

NeoGenomics, Inc. (NASDAQ: NEO) shares moved higher after the company reported second-quarter 2026 results that exceeded analyst expectations and raised its full-year revenue outlook.

• Positive Sentiment: Q2 earnings beat estimates: NeoGenomics reported adjusted earnings of $0.05 per share, ahead of the $0.03 FactSet consensus. Revenue reached $201.66 million, exceeding analysts’ $196.93 million forecast. NeoGenomics Q2 adjusted EPS result
• Positive Sentiment: Full-year outlook increased: Management raised its fiscal 2026 revenue guidance to $802 million-$806 million, above the approximately $800.3 million analyst consensus. The higher outlook suggests continued demand and supports the positive investor reaction. NeoGenomics second-quarter results
• Positive Sentiment: Improving operating performance: Reports characterized the quarter as showing growth in both profit and revenue, with results described as outperforming expectations and the full-year outlook upgraded. NeoGenomics exceeds Q2 expectations
• Neutral Sentiment: Analyst stance remains cautious: NeoGenomics carries a consensus “Hold” rating, indicating that some investors may view the improved results and guidance as largely reflected in the stock’s recent gains. NeoGenomics consensus analyst rating
• Negative Sentiment: Profitability remains a concern: Despite the quarterly earnings beat, the company reported a negative net margin of 13.30% and negative return on equity of 2.80%, highlighting ongoing profitability risks.